| Incidence and risk factors for hypertension among HIV patients in rural Tanzania–A prospective cohort study E Rodríguez-Arbolí, K Mwamelo, AV Kalinjuma, H Furrer, C Hatz, ... PloS one 12 (3), e0172089, 2017 | 89 | 2017 |
| Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study D Martínez-Cuadrón, JE Megías-Vericat, J Serrano, P Martínez-Sánchez, ... Blood advances 6 (4), 1278-1295, 2022 | 42 | 2022 |
| Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries C Récher, C Röllig, E Bérard, S Bertoli, PY Dumas, S Tavitian, M Kramer, ... Leukemia 36 (4), 913-922, 2022 | 41 | 2022 |
| FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the … E Rodríguez-Arbolí, M Labopin, J Tischer, A Brecht, A Ganser, J Finke, ... Biology of Blood and Marrow Transplantation 26 (11), 2165-2173, 2020 | 24 | 2020 |
| Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult … C Orvain, JA Wilson, M Fang, BM Sandmaier, E Rodríguez-Arbolí, ... Haematologica 108 (2), 420, 2023 | 14 | 2023 |
| Long-term outcomes after autologous versus allogeneic stem cell transplantation in molecularly-stratified patients with intermediate cytogenetic risk acute myeloid leukemia: a … E Rodríguez-Arbolí, D Martínez-Cuadrón, R Rodríguez-Veiga, ... Transplantation and cellular therapy 27 (4), 311. e1-311. e10, 2021 | 12 | 2021 |
| Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell … E Rodríguez-Arbolí, M Othus, C Orvain, LC Zarling, BM Sandmaier, ... Haematologica 108 (1), 273, 2023 | 8 | 2023 |
| Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA registry J Labrador, D Martínez-Cuadrón, A De La Fuente, R Rodríguez-Veiga, ... Cancers 14 (9), 2342, 2022 | 8 | 2022 |
| Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group C Sargas, R Ayala, MJ Larráyoz, MC Chillón, E Rodriguez-Arboli, ... Blood Cancer Journal 13 (1), 77, 2023 | 7 | 2023 |
| SF3B1, RUNX1 and TP53 mutations significantly impact the outcome of patients with lower-risk myelodysplastic syndrome JF Falantes, FJ Márquez-Malaver, E Carrillo, MG Culebras, R Morales, ... Clinical Lymphoma Myeloma and Leukemia 22 (12), e1059-e1066, 2022 | 6 | 2022 |
| Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation E Rodriguez-Arboli, C Orvain, M Othus, RB Walter Bone marrow transplantation 57 (11), 1732-1734, 2022 | 6 | 2022 |
| Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML AB Halpern, E Rodríguez-Arbolí, M Othus, KLA Garcia, MEM Percival, ... Blood Advances 7 (17), 4950-4961, 2023 | 4 | 2023 |
| Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or … RB Walter, BM Sandmaier, M Othus, C Orvain, E Rodríguez-Arbolí, ... Bone marrow transplantation 58 (4), 377-385, 2023 | 4 | 2023 |
| Association between prior cytotoxic therapy, antecedent hematologic disorder, and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia C Orvain, E Rodríguez-Arbolí, M Othus, BM Sandmaier, HJ Deeg, ... Cancers 15 (2), 352, 2023 | 4 | 2023 |
| Long-term impact of an educational antimicrobial stewardship program on management of patients with hematological diseases AB Guisado-Gil, M Aguilar-Guisado, G Peñalva, JA Lepe, I Espigado, ... Antibiotics 10 (2), 136, 2021 | 4 | 2021 |
| Allocation to matched related or unrelated donor results in similar clinical outcomes without increased risk of failure to proceed to transplant among patients with acute … E Rodríguez-Arbolí, FJ Márquez-Malaver, N Rodríguez-Torres, ... Biology of Blood and Marrow Transplantation 25 (1), 183-190, 2019 | 4 | 2019 |
| Phase 1/2 trial of CLAG-M with dose-escalated mitoxantrone in combination with fractionated-dose gemtuzumab ozogamicin for newly diagnosed acute myeloid leukemia and other high … CD Godwin, E Rodríguez-Arbolí, M Othus, AB Halpern, JS Appelbaum, ... Cancers 14 (12), 2934, 2022 | 3 | 2022 |
| Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia D Martínez-Cuadrón, J Serrano, J Mariz, C Gil, M Tormo, ... Cancers 14 (11), 2817, 2022 | 2 | 2022 |
| Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid … AB Halpern, EP Rodríguez-Arbolí, M Othus, KLA Garcia, MEM Percival, ... Blood 140 (Supplement 1), 8999-9001, 2022 | 1 | 2022 |
| Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis E Rodríguez-Arbolí, M Labopin, M Eder, A Brecht, IW Blau, A Huynh, ... Bone Marrow Transplantation 57 (6), 934-941, 2022 | 1 | 2022 |
